One area of the share market that I believe has extremely bright long-term growth prospects is the healthcare sector. I think the sector is home to several high quality up and coming companies which investors should be better acquainted with.
Three that have caught my eye are listed below. Here's why I like them:
Medical Developments International Ltd (ASX: MVP)
This healthcare company has been around for decades, but only recently has it decided to embark on a global expansion project with its Penthrox "green whistle" pain management product. Management believes there is a huge opportunity for the product to disrupt the pain management market at the expense of opioids and I completely agree. However, its shares do change hands on sky-high multiples now, which does make it a high-risk investment. Though, if its global expansion is a success it could more than justify the premium.
Paragon Care Ltd (ASX: PGC)
Paragon Care is a provider of integrated services to the health and aged care markets. I think it is one of the more promising small cap healthcare shares, especially after its recently announced acquisition of REM Systems for a net enterprise value of NZ$54.4 million. Though there are integration risks to consider, I remain optimistic that management will make a success of this. This should put Paragon Care in a position to deliver solid top and bottom line growth over the coming years. So with its shares trading at a reasonable 15x estimated forward earnings, now could be an opportune time to consider a buy and hold investment.
Zenitas Healthcare Ltd (ASX: ZNT)
Another small cap healthcare share that I think could be a great buy and hold option is Zenitas Healthcare. This year the home care and health services company is expecting to report earnings before interest, tax, depreciation, and amortisation of between $13 million and $13.5 million. With its market capitalisation hovering around the $80 million mark, I think this makes it great value. Especially given its solid growth prospects from two recent earnings accretive acquisitions and a favourable Federal Budget which should be a tailwind for the company in the medium-term.
